A Phase 4 interventional study of LAF237 (vildagliptin) and Metformin in Type-2 Diabetes Mellitus, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 69th largest by enrollment of the 118 interventional ones that give a count, is one of 9 that started in 2013, is one of 43 in phase 4, and was the 93rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 65 · Phase 4 43
First in 2003; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 162 across the 118 interventional studies. Of the 113 that completed or were terminated, 13 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 119 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
122 studies in Diabetes Mellitus, Type 2 by Novartis: none open now, none under way, none of them phase 3. Of 121 finished, 27 (22%) have results posted.
Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, this one is the 79th largest by enrollment of the 121 interventional ones that give a count, is one of 9 that started in 2013, is one of 30 in phase 4, and was the 108th registered.
Novartis’s Diabetes Mellitus, Type 2 studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 122 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.
Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
Drug: LAF237 (vildagliptin) · Drug: Metformin
Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
Drug: LAF237 (vildagliptin) · Drug: Metformin
Vildagliptin 50mg capsule
Also known as: LAF237
Metformin maximum tolerance dose
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12
HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c
Time frame: Baseline, Month 12 (weeK 52)
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)
HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.
Time frame: Baseline, Month 3, 6, 9 and 12
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)
Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.
Time frame: Baseline, Month 3, 6, 9 and 12
Percentage of Patients Achieving Good Glycemic Control
Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.
Time frame: Month 3, 6, 9, 12
Percentage of Overall Drug Compliance in 12 Months
The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits × No. of Days between the Date Dispensed and the Date Returned))\]
Time frame: Month 12
Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability
This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.
Time frame: Month 12
| Milestone | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| Started | 56 | 61 |
| Completed | 51 | 57 |
| Not completed | 5 | 4 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 |
HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c
| percentage of Glycosylated Hemoglobin | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12 | -0.8 ± 1.01 | -1.0 ± 1.24 |
HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.
| percentage of Glycosylated Hemoglobin | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| 3 month from baseline | -0.6 ± 0.11 | -0.9 ± 0.10 |
| 6 month from baseline | -0.7 ± 0.13 | -0.9 ± 0.12 |
| 9 month from baseline | -0.7 ± 0.13 | -0.7 ± 0.13 |
| 12 month from baseline | -0.6 ± 0.15 | -0.6 ± 0.15 |
Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.
| mmol/L | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| 3 month from baseline | -0.9 ± 0.18 | -1.3 ± 0.16 |
| 6 month from baseline | -1.2 ± 0.18 | -0.9 ± 0.17 |
| 9 month from baseline | -1.1 ± 0.17 | -1.0 ± 0.16 |
| 12 month from baseline | -0.9 ± 0.20 | -0.8 ± 0.20 |
Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.
| Percentage of patients | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| At Month 3 | 33.3 | 47.5 |
| At Month 6 | 39.2 | 45.6 |
| At Month 9 | 45.1 | 47.4 |
| At Month 12 | 49.0 | 40.0 |
The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits × No. of Days between the Date Dispensed and the Date Returned))\]
| Percentage of overall drug compliance | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| Percentage of Overall Drug Compliance in 12 Months | 96.90 ± 5.682 | 97.48 ± 6.277 |
This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.
| Patients | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| Any adverse events | 15 | 14 |
| Serious adverse events | 2 | 2 |
| Death | 0 | 0 |
| Patients discontinued due to any AE/SAE | 4 | 4 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAF237 (Vildagliptin) 50mg Once Daily (QD) | — | 2/56 (3.6%) | 14/56 (25%) |
| LAF237 (Vildagliptin) 50mg Twice Daily (BID) | — | 2/61 (3.3%) | 7/61 (11.5%) |
| Event | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| DuodenitisGastrointestinal disorders | 1/56 | 0/61 |
| stone impairation over proximal urethraRenal and urinary disorders | 1/56 | 0/61 |
| LeukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 1/61 |
| Renal failureRenal and urinary disorders | 0/56 | 1/61 |
| Event | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 8/56 | 2/61 |
| Elevated liver function testInvestigations | 2/56 | 2/61 |
| HypokalemiaMetabolism and nutrition disorders | 2/56 | 0/61 |
| DizzinessNervous system disorders | 2/56 | 1/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/56 | 2/61 |
| EczemaSkin and subcutaneous tissue disorders | 2/56 | 1/61 |
| TineaInfections and infestations | 0/56 | 2/61 |
| HyperkalemiaMetabolism and nutrition disorders | 1/56 | 2/61 |
Intent to treat (ITT) included all randomized patients who received at least one dose of study medication.
| Age, Continuous(Years) | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) | Total |
|---|---|---|---|
| Mean | 58 ± 10.3 | 59 ± 10.0 | 58 ± 10.1 |
| Sex: Female, Male(Participants) | LAF237 (Vildagliptin) 50mg Once Daily (QD) | LAF237 (Vildagliptin) 50mg Twice Daily (BID) | Total |
|---|---|---|---|
| Female | 26 | 31 | 57 |
| Male | 30 | 30 | 60 |
Ran from May 2013 to primary completion in Oct 2015, 29 months.
Results were first posted in Apr 2017, 1 year 5 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 29 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vildagliptin · Metformin